Welcome Center  |   Log In  |   Register  |   Follow Us  Facebook  Twitter Google Plus

Latest in Best Practice Series: Type 2 Diabetes

Reuters Health • The Doctor's Channel Daily Newscast

Metformin still best first-line oral hypoglycemic drug for type 2 diabetes

NEW YORK (Reuters Health) – An updated review of medications available for treating type 2 diabetes concludes that metformin continues to have the best benefit-to-harm profile, according to a report in the Annals of Internal Medicine online March...

Compounds that effect GLP-1, GIP and DPP-4.

The Incretin Pathway: A new area of treatment for Type 2 diabetes.

Zachary Bloomgarden, MD, Editor of The Journal of Diabetes and Clinical Professor in the Dept. of Medicine at the Mount Sinai School of Medicine, discusses the use of drugs that affect the incretin pathway in treating diabetes. Disclosures:Speaker’s...
Zachary Bloomgarden, MD, Editor of The Journal of Diabetes and Clinical Professor in the Dept. of Medicine at the Mount Sinai School of Medicine, discusses screening of various microvascular complications of type 2 diabetes and evaluates their...